Fig. 2From: Changes in plasma biomarkers following treatment with cabozantinib in metastatic castration-resistant prostate cancer: a post hoc analysis of an extension cohort of a phase II trialSchematic representation of the significant alterations in plasma biomarkers during treatment with cabozantinib. Asterisk signifies a corrected p value (based on the Bonferroni correction for multiple comparisons) <0.05Back to article page